Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Capital Reinvestment Ratio
Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Capital Reinvestment Ratio of 0.19x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥281.88 Million) in capital expenditures (CN¥54.40 Million). See 605033 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shaanxi Meibang Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Shaanxi Meibang Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 7 annual periods. Check 605033 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see Shaanxi Meibang Pharmaceutical Group Co (605033) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | CN¥280.40 Million | CN¥158.81 Million | ▼ -6.9% |
| 2023 | 0.61x | CN¥334.79 Million | CN¥203.69 Million | ▼ -29.6% |
| 2022 | 0.86x | CN¥126.41 Million | CN¥109.29 Million | ▲ +4.9% |
| 2020 | 0.82x | CN¥74.88 Million | CN¥61.71 Million | ▲ +213.4% |
| 2019 | 0.26x | CN¥128.45 Million | CN¥33.78 Million | ▼ -87.2% |
| 2018 | 2.06x | CN¥16.96 Million | CN¥34.86 Million | ▲ +244.2% |
| 2017 | 0.60x | CN¥29.41 Million | CN¥17.56 Million | — |